Anavex Life Sciences’ (AVXL) “Buy” Rating Reiterated at D. Boral Capital

D. Boral Capital restated their buy rating on shares of Anavex Life Sciences (NASDAQ:AVXL) in a research report report published on Tuesday,Benzinga reports. They currently have a $46.00 price target on the biotechnology company’s stock.

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $42.00 target price on shares of Anavex Life Sciences in a research note on Tuesday, January 21st.

Anavex Life Sciences Stock Down 1.3 %

Anavex Life Sciences stock opened at $9.57 on Tuesday. The firm has a market capitalization of $811.73 million, a PE ratio of -18.40 and a beta of 0.70. Anavex Life Sciences has a 52 week low of $3.25 and a 52 week high of $14.44. The firm’s 50-day simple moving average is $9.99 and its 200 day simple moving average is $7.52.

Anavex Life Sciences (NASDAQ:AVXL) last announced its earnings results on Monday, December 23rd. The biotechnology company reported ($0.14) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.03. On average, research analysts expect that Anavex Life Sciences will post -0.73 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Nwam LLC acquired a new stake in shares of Anavex Life Sciences during the 3rd quarter worth about $5,172,000. Renaissance Technologies LLC boosted its position in Anavex Life Sciences by 483.8% during the second quarter. Renaissance Technologies LLC now owns 466,437 shares of the biotechnology company’s stock worth $1,968,000 after acquiring an additional 386,537 shares during the last quarter. Barclays PLC grew its stake in Anavex Life Sciences by 70.4% in the 3rd quarter. Barclays PLC now owns 155,179 shares of the biotechnology company’s stock worth $882,000 after acquiring an additional 64,101 shares during the period. Geode Capital Management LLC grew its stake in Anavex Life Sciences by 2.8% in the 3rd quarter. Geode Capital Management LLC now owns 1,883,199 shares of the biotechnology company’s stock worth $10,699,000 after acquiring an additional 51,946 shares during the period. Finally, Squarepoint Ops LLC acquired a new position in Anavex Life Sciences in the 2nd quarter valued at $191,000. Institutional investors and hedge funds own 31.55% of the company’s stock.

Anavex Life Sciences Company Profile

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome.